Combination treatment with dendrosomal nanocurcumin and doxorubicin improves anticancer effects on breast cancer cells through modulating CXCR4/NF-κB/Smo regulatory network
- 340 Downloads
Despite advantageous antitumor properties of doxorubicin, the considerable cytotoxicity of this chemotherapeutic agent has made it necessary to develop combination treatment strategies. The aim of the current study was to investigate the possible synergism between dendrosomal nanocurcumin (DNC) and doxorubicin in eliciting anticancer effects on MDA-MB-231 metastatic breast cancer cells. The expression levels of CXCL12/CXCR4 axis and Hedgehog pathway genes were evaluated in patient-derived breast carcinoma tissues by qRT-PCR. MTT assay, Annexin V-FITC staining followed by flowcytomety and wound healing assay were used to measure the effects caused by DNC and doxorubicin, alone and in combination, on the viability, apoptosis induction, and migration of MDA-MB-231 cells, respectively. Also, qRT-PCR was exploited to analyze the expression of Smo, NF-κB and CXCR4 in cancer cells. Our results revealed that combination treatment with DNC and doxorubicin leads to significantly decreased viability, increased apoptosis, and reduced migration of breast cancer cells compared with using each drug alone. Also, combination treatment is more efficient that single treatment in reducing the expression levels of NF-κB and Smo transcripts. Our findings provide convincing support for the notion that DNC could synergistically enhance the anticancer effects of doxorubicin on metastatic breast cancer cells by improving its anti-proliferative, pro-apoptotic, and anti-migratory activities. This may be mediated, in part, by downregulating CXCR4, NF-κB, and Smo genes. Overall, the findings of the current study suggest that DNC might be used as a synergistic agent for enhancing therapeutic efficiency and reducing toxic effects of doxorubicin on breast cancer cells.
KeywordsBreast cancer Combination treatment Dendrosomal nanocurcumin Doxorubicin Synergism
This work was supported by a research grant from Tarbiat Modares University.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Ferlay J, Soerjomataram I, Ervik M (2012) GLOBOCAN, cancer incidence and mortality worldwide: IARC cancer base no. 11 [Internet]. International Agency for Research on Cancer, Lyon; 2013Google Scholar
- 5.Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz -Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK (2007) Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor- κ B pathway. Clin Cancer Res 13(11):3423–3430CrossRefPubMedGoogle Scholar
- 8.Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB (2006) Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of I κ B α kinase and Akt activation. Mol Pharmacol 69(1):195–206PubMedGoogle Scholar
- 10.Sen GS, Mohanty S, Hossain DMS, Bhattacharyya S, Banerjee S, Chakraborty J, Saha S, Ray P, Bhattacharjee P, Mandal D (2011) Curcumin enhances the efficacy of chemotherapy by tailoring p65NFκB-p300 cross-talk in favor of p53-p300 in breast cancer. J Biol Chem 286(49):42232–42247CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Chen W-C, Lai Y-A, Lin Y-C, Ma J-W, Huang L-F, Yang N-S, Ho C-T, Kuo S-C, Way T-D (2013) Curcumin suppresses doxorubicin-induced epithelial–mesenchymal transition via the inhibition of TGF - β and PI3K/AKT signaling pathways in triple-negative breast cancer cells. J Agric Food Chem 61(48):11817–11824CrossRefPubMedGoogle Scholar
- 12.Notarbartolo M, Poma P, Perri D, Dusonchet L, Cervello M, D’Alessandro N (2005) Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression. Cancer Lett 224(1):53–65CrossRefPubMedGoogle Scholar
- 19.Siddiqui IA, Adhami VM, Chamcheu J, Mukhtar H (2012) Impact of nanotechnology in cancer: emphasis on nanochemoprevention. Int J Nanomed 7:591–605Google Scholar
- 23.Mirgani MT, Isacchi B, Sadeghizadeh M, Marra F, Bilia AR, Mowla SJ, Najafi F, Babaei E (2014) Dendrosomal curcumin nanoformulation downregulates pluripotency genes via miR -145 activation in U87MG glioblastoma cells. Int J Nanomed 9(1):403–417Google Scholar
- 30.Mohajeri M, Sadeghizadeh M, Najafi F, Javan M (2015) Polymerized nano-curcumin attenuates neurological symptoms in EAE model of multiple sclerosis through down regulation of inflammatory and oxidative processes and enhancing neuroprotection and myelin repair. Neuropharmacology 99:156–167CrossRefPubMedGoogle Scholar
- 42.Chen J-S, Huang X-h, Wang Q, Huang J-Q, Zhang L-j, Chen X-L, Lei J, Cheng Z-X (2012) Sonic Hedgehog signaling pathway induces cell migration and invasion through focal adhesion kinase/AKT signaling–mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9 in liver cancer. Carcinogenesis. doi: 10.1093/carcin/bgs274 Google Scholar
- 46.Woo J-H, Kim Y-H, Choi Y-J, Kim D-G, Lee K-S, Bae JH, Chang J-S, Jeong Y-J, Lee YH, Park J-W (2003) Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl -XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis 24(7):1199–1208CrossRefPubMedGoogle Scholar
- 49.Singh AP, Arora S, Bhardwaj A, Srivastava SK, Kadakia MP, Wang B, Grizzle WE, Owen LB, Singh S (2012) CXCL12/CXCR4 signaling axis induces SHH expression in pancreatic cancer cells via ERK-and Akt-mediated activation of NF-κB: implications for bidirectional tumor-stromal interactions. J Biol Chem. doi: 10.1074/jbc.M112.409581 Google Scholar